Dequalinium analogs

Details Dequalinium analogs Dequalinium analogs

2002-12-24

2004-09-14

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S153000, C546S159000

Reexamination Certificate

active

06790962

ABSTRACT:

BACKGROUND
Dequalinium (C10-DECA) (quinolinium, 1,1′-(1,10-decanediyl) bis (4-amino-2-methyl diiodide) (see 1c in Table 1) was sold for over thirty years as an antimicrobial agent and the active ingredient in mouthwash and other topical formulations. Since 1987, C10-DECA has been studied as a potent antitumor agent that recognizes several isoforms (e.g., &agr;, &bgr;1) of protein kinase C (PKC) in vitro (IC50=10-14 &mgr;M) and in cells
1,2
. This monomeric serine/threonine protein kinase consists of a family of eleven structurally-related isoforms and is well-known for its role in cellular signaling pathways that govern normal cell growth and differentiation
3
. Because of its function in tumor formation and metastasis, PKC continues to attract interest as a target for new chemotherapeutic agents.
A potent anti-tumor agent in several animal models
4
, C10-DECA is accumulated by transformed cells in culture to a greater extent than by non-transformed cells
5,6
. C10-DECA inhibits PKC activity in vitro and in cells at low micromolar concentrations
1,2
by interfering with binding sites in both the regulatory
1,2
and catalytic domains
2,7
. Inhibition of catalytic activity involves a site or sites located in the catalytic domain of PKC
&agr;
2,7
, but an additional C10-DECA recognition site in the regulatory domain involving the RACK-1 (Receptor for Activated C-Kinase) binding domain has also been demonstrated
1
.
A series of PKC
&agr;
mutants that represented progressive truncation from the amino-terminus (regulatory domain) have been tested for sensitivity to inhibition to C10-DECA in order to examine the importance of the regulatory domain to C10-DECA-mediated inhibition of catalytic activity. That analysis revealed that the sites of interaction in the regulatory and catalytic domains are independent of each other, and that the site at which C10-DECA produces inhibition of catalytic activity lies exclusively in the catalytic domain
7
. One of the inventors (SAR) has tested structurally homologous protein kinases for inhibition, and found them to be insensitive to micromolar C10-DECA concentrations. The homologous protein kinases included the cAMP-dependent protein kinase (PKA), the calmodulin-dependent myosin light chain kinase, and the pp60
src
tyrosine protein kinase. The finding that PKA is insensitive to DECA at high micromolar concentrations is compelling in view of the close sequence homology of the PKC and PKA catalytic domains. With respect to these other protein kinases, the key site recognized by C10-DECA is apparently unique to PKC. Additional cellular targets of C10-DECA have been reported, however, namely the mitochondrial F1-ATPase
8
, calmodulin-dependent phosphodiesterase
9
, and the calcium-activated K
+
-channel
10
.
An unusual property of C10-DECA is that it can be photolyzed with longwave UV light, which converts it into an irreversible inhibitor of PKC activity
1
. Photoreactivity was previously employed to demonstrate inactivation of recombinant PKC
&agr;
activity in vitro and PKC
&agr;
translocation in cells
1
.
There is a need, however, to optimize the ability of C10-DECA to inhibit the activity of an isoform of protein kinase C, especially protein kinase C
&agr;
. There is a particular need to optimize the beneficial manifestations of inhibiting the activity of an isoform of protein kinase C, such as inhibiting the motility of pre-cancerous cells, inhibiting the growth of pre-cancerous or malignant cells, and inhibiting the metastasis of malignant cells.
SUMMARY OF THE INVENTION
In one embodiment, the invention relates to a chemical compound having the formula:
(Q-L-Q)
w
+2
X
y
−z
  (Formula 1)
or
(Q-T)
u
+
X
−v
  (Formula 2)
wherein:
Q represents 4-E-2-R
3
-1-quinolinium;
E represents NR
1
R
2
, COO R
1
, OR
1
, I, Br, Cl, F, or NO
3
N represents a nitrogen atom;
R
1
and R
2
independently represent hydrogen or lower alkyl;
R
3
represents E, hydrogen or lower alkyl;
L represents a chain comprising n atoms, the atoms in the chain being t carbon atoms and 0 to approximately 0.5t heteroatoms;
the minimum value of n is 12;
the maximum value of n is 22;
T represents hydrogen or a chain comprising m atoms, the atoms in the chain being t carbon atoms and 0 to approximately 0.5t heteroatoms;
the minimum value of m is 6;
the maximum value of m is 22;
X represents an anion;
w represents 1 or 3, y represents 1 or 2 and z represents 1, 2 or 3, with the proviso that 2w=yz; and
u and v represent 1, 2, or 3 with the proviso that u=v.
In another embodiment, the invention relates to a chemical compound having the formula:
(Q-L-Q)
+2
X
y
−z
or (Q-T)
+
X
1
wherein:
Q represents 4-NR
1
R
2
-2-R
3
-1-quinolinium;
N represents a nitrogen atom;
R
1
and R
2
independently represent hydrogen or lower alkyl;
R
3
represents hydrogen or lower alkyl;
L represents a 1,n-aliphatic chain comprising n carbon atoms;
n represents 12-22;
T represents hydrogen or a 1,m-aliphatic chain comprising m carbon atoms;
m represents 6-22;
X represents an anion; and
y and z represent 1 or 2 with the proviso that yz=2.
In yet another embodiment, the invention relates to a composition for protecting human skin from harmful effects of the sun. The composition comprises a topically effective amount of a first chemical compound that absorbs ultraviolet light sufficiently to reduce significantly the damage to human skin from harmful effects of the sun and a second chemical compound having any of the structures described above, including Formula 1 or Formula 2.
In a further embodiment, the invention relates to a method for inhibiting the activity of an isoform of protein kinase C. The method comprises contacting the protein kinase C with an effective amount of a chemical compound having any of the structures described above, including Formula 1 or Formula 2.
In yet another embodiment, the invention relates to a method for inhibiting the motility of cells. The method comprises contacting the cells with an effective amount of a chemical compound having any of the structures described above, including Formula 1 or Formula 2.
In still another embodiment, the invention relates to a method for inhibiting the metastasis of malignant cells in a mammal. The method comprises treating the mammal with an effective amount of a chemical compound having any of the structures described above, including Formula 1 or Formula 2.
In yet a further embodiment, the invention relates to a method for inhibiting the growth of pre-cancerous or malignant cells in a mammal. The method comprises treating the mammal with an effective amount of a chemical compound having any of the structures described above, including Formula 1 or Formula 2.


REFERENCES:
patent: 5208011 (1993-05-01), Vaughan
patent: 5914102 (1999-06-01), Fowler et al.
patent: 6090619 (2000-07-01), Weissig et al.
patent: 6171863 (2001-01-01), Weissig et al.
patent: 2001/0001067 (2001-05-01), Weissig et al.
Galanakis, J. Med. Chem, vol 39, pp 3592-3595, 1996.*
Qin, J Med Chem, vol 43, pp 1413-1417, 2000.*
Medline abstract 1999402168, abstract of Lancet, vol 354 (9180), pp 723-729, 1999.*
Qin, et al.; “Inhibition of Protein Kinase C&agr; by Dequalinium Analogues: Dependence on Linker Length and Geometry,” Journal of Medicinal Chemistry, vol. 43, No. 7, pp. 1413-1417; (2000).
Sullivan, et al.; “Photo-Induced Inactivation of Protein Kinase C&agr; by Dequalinium Inhibits Motility of Murine Melanoma Cells,” Molecular Pharmacology, vol. 58, No. 4, pp. 729-737; (2000).
Rotenberg, et al.; “Deletion Analysis of Protein Kinase C&agr; Reveals a Novel Regulatory Segement,” J. Biochem., vol. 124, pp. 756-763; (1998).
Galanakis, et al.; “Synthesis and Quantitative Structure-Activity Relationships of Dequalinium Analogues as K+ channel Blockers :Investigation into the Role of the Substituent at Position 4 of the Quinoline Ring,” J. Med. Chem. 38: 3536-3546 (1995).
Galanakis, et al.; “Synthesis and Quantitative Structure-Activity Relationships of Dequalinium Analogues

Affiliated with

Also associated with

Rating

Dequalinium analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dequalinium analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dequalinium analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3226619